Stocks · News reference

Agomab Therapeutics Announces Results From 48-Week OLE Portion Of Its Phase 2A STENOVA Trial Evaluating Ontunisertib In Patients With Severe Crohn's Disease; Favorable Safety And Tolerability Profile Maintained Through Up To 60 Weeks Of Treatment; Low Annualized FSCD-Related Event Rate Of 3%

2026-10-01 10:38:29 UTCBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.ai2026-11-06 16:32:22 UTC
AgomAb Therapeutics NV Form 4 Filing
AgomAb Therapeutics NV reported a Form 4 filing on November 6, 2026, regarding activity from November 5, 2026, filed by David R. Epstein.
AGMB
Fiscal.ai2026-11-05 08:02:09 UTC
Agomab Therapeutics Announces Participation in Upcoming Investor Conferences
Agomab Therapeutics NV announced that its management team will participate in several upcoming healthcare investor conferences throughout November and December 2026.
AGMB
Fiscal.ai2026-10-23 07:02:02 UTC
Insider Stock Purchases at AgomAb Therapeutics NV
AgomAb Therapeutics NV reported insider stock purchases by board member David R. Epstein on October 22, 2026.
AGMB
Benzinga2026-10-13 20:06:27 UTCBenzinga Newsdesk
Agomab Therapeutics Doses First Patient In NOV-ERA, Global Phase 2b Study Evaluating Ontunisertib In Patients With Symptomatic FSCD
AGMB
Benzinga2026-10-08 20:07:23 UTCBenzinga Newsdesk
Agomab Therapeutics To Present Open-Label Extension Data For Ontunisertib In Fibrostenosing Crohn's Disease At UEG Week On October 20
AGMB
Benzinga2026-10-01 18:31:03 UTCVandana Singh
Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial
Agomab Therapeutics reports positive 48-week Phase 2a trial data for ontunisertib in patients with fibrostenotic Crohn's disease.
AGMB